Abstract
The implications of the proceedings gathered here are increasingly important. Despite the powerful evidence generated by the findings of primary- and secondary-prevention trials—such as the West of Scotland Coronary Prevention Study (WOSCOPS),1 the Cholesterol and Recurrent Events (CARE) trial,2 and the Scandinavian Simvastatin Survival Study (4S),3—we still do not have all the answers regarding management of dyslipidemias in the prevention of coronary artery disease (CAD). The major emphasis of these and other angiographic and clinical outcome trials, and of the National Cholesterol Education Program (NCEP) guidelines,4 has been on lowering plasma low-density lipoprotein (LDL) cholesterol levels as the means to halting or reversing disease progression and decreasing morbidity and mortality. As the investigators of the following articles point out, however, whereas elevated LDL cholesterol may be a critical coronary risk factor, it is but one of several lipid abnormalities that may be important contributors to CAD riskAntonio M. Gotto, Jr.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
